Research · Sep 3, 2026
CVS Health's FY2025 showed partial HCB Medical Benefit Ratio recovery toward 90-91% from the 92%+ FY2024 disaster, lifting adj. EPS to ~$6.25 from ~$5.11 trough. CEO Joyner filed significant FY2026 MA premium increases with CMS and tightened GLP-1/behavioral health prior authorization. FY2026 is the binary test: do pricing actions restore HCB MBR to 87-88%, enabling EPS recovery toward $7.50-8.00? Or does utilization continue surprising to upside, keeping CVS in the earnings rebuild cycle through FY2027?
Research · Apr 13, 2026
Trump's proposed 100% pharma tariffs and China's biotech surge, per April 11 CNBC, threaten Europe's manufacturing edge, hiking costs for PFE (-2.8% 1M) and MRK (-5.1% 1M) while LLY's US focus drives 25% 2026 growth. Supply chain filings flag $100-200M hits; investors should fade exposed names, buy domestic leaders. Next catalysts: Earnings tariff disclosures and China trade flows.
Research · Apr 10, 2026
CVS Health's recent settlement with the FTC over insulin pricing marks a pivotal moment in the pharmaceutical landscape. This article analyzes the potential winners and losers among pharmacies and drugmakers as regulatory scrutiny intensifies, highlighting key players like Eli Lilly, Novo Nordisk, and Walgreens Boots Alliance.
Research · Apr 9, 2026
Trump's April 2 pharma tariff announcement highlights supply chain risks for LLY, TMO, and CVS, with SEC filings exposing China reliance. Stocks dipped mildly, but domestic manufacturing offers protection amid margin pressures.
Research · Apr 9, 2026
The April 7, 2026, Medicare Advantage rate decision sparked gains for UNH and HUM, signaling margin relief for exposed insurers. UNH leads with balanced exposure and scale, followed by HUM's pure-play bet and CI's value. Rankings prioritize MA leverage, growth, and valuations amid stabilizing reimbursements.
